Broad spectrum antivirals The group identified active compounds against emerging viruses (i e Zika, Dengue, SARS COV 2). Analysis of novel foods and circular economy Study the upcycling by products in insects Analysis of the influence insect derived components in the prevention of cardiovascular diseases
Our research activity adopts a ONE HEALTH approach while applying post genomics (proteomics, metabolomics), cell biology, biochemistry, computational biochemistry and AI in Life Sciences, sustainable pharmaceuticals and circular bioeconomy.
The research group works in the following fields: development of epigenetic and non-epigenetic modulators for the treatment of hematologic tumors. design and synthesis of inhibitors targeting enzymes of the endocannabinoid system for the development of therapeutic agents for neurodegenerative diseases and epilepsy treatment. synthesis of new pharmacological tools for the treatment of rare diseases. Design and synthesis of enzymatic inhibitors or receptor modulators for the development of new infectious agents. Green chemistry methods for the development of new neurodegeneration modulators.
The research activities of the group are focused on the development, preparation, and characterization of intelligent nanomaterials, particularly: development of polysaccharide and lipid-based nanocarriers. development of tissue substitutes. drafting of analysis protocols. conformational and dynamic analysis of biomolecules
The research activities of the BioStructLab are focus on gene manipulation by recombinant DNA technique, production of biological macromolecules ( RNA and DNA), and structural characterization by structural biology techniques The
The research group is focused on two key areas, synthetic organic chemistry and computational chemistry, which are highly complementary and in complete synergy with each other. the research group is interested in the development of new chemical methodologies in the medicinal chemistry context and in the study of the interaction between the drug and its macromolecular target
The patent application protects nontoxic small molecules (glycomimetics), easily obtained from natural compounds (carbohydrates), which can be used for personalized treatment of glycan-related diseases
The invention concers compounds that act directly on the extracellular virus.
The invention consists of alternative compounds to nitisinone, for the treatment of both AKU and HT1.
The present invention serves the development of new therapeutic strategies and new non-opioid drugs for the treatment of pain
